Cogent Biosciences Q2 2026: $96.4M Net Loss, $865.9M Pro Forma Cash, and PDUFA Dates Set for Bezuclastinib
COGT has more than doubled off its 52-week low of $10.38.
Summary
Cogent Biosciences reported Q2 2026 financial results with a $96.4 million net loss, a pro forma cash balance of $865.9 million, and confirmed PDUFA dates of November 30 and December 30 for bezuclastinib in GIST and NonAdvSM, respectively.
Key Events · Earnings and Guidance · COGT
-
Q2 2026 Net Loss Widens
Net loss was $96.4 million, up from $73.5 million in Q2 2025, driven by higher R&D ($70.8M) and G&A ($31.8M) expenses as the company prepares for commercial launch.
-
Strong Cash Position
Cash, cash equivalents, and marketable securities were $792.3 million as of June 30, 2026. Including $73.6 million in ATM proceeds after quarter-end, pro forma cash is $865.9 million, funding operations into late 2028.
-
PDUFA Dates Confirmed
FDA set PDUFA dates of November 30, 2026 for bezuclastinib in GIST and December 30, 2026 for NonAdvSM, with priority review for the GIST indication.
-
Inducement Grants to New Hires
The company granted 226,700 stock options and 189,700 RSUs to 59 new employees under its inducement plan, reflecting commercial team build-out.
Analysis · COGT · Life Sciences
Cogent reported a wider Q2 net loss of $96.4 million as it ramps up commercial readiness for bezuclastinib, with two PDUFA dates now set for late 2026. The quarter ended with $792.3 million in cash, and an additional $73.6 million was raised through the ATM after quarter-end, extending the runway into late 2028 — enough to fund through potential approvals and early launches. The filing also details inducement grants to 59 new employees, signaling aggressive hiring ahead of commercialization. While the loss is larger than last year, the cash position and regulatory clarity are the dominant takeaways.
At the time of this filing, COGT was trading at $40.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2B. The 52-week trading range was $10.38 to $43.73. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.